ALC.SW Alcon (SIX) 23 Feb 2026 market closed: CHF63.78 ahead of earnings
ALC.SW stock closed at CHF 63.78 on 23 Feb 2026 as markets shut ahead of Alcon’s quarterly report. The eye-care group reports results on 24 Feb 2026, and investors watch revenue, surgical procedure volumes, and margin recovery. Current metrics show EPS 1.61 and PE 39.93, with volume at 1,077,533 shares. This earnings spotlight focuses on what the numbers imply for price action on the SIX Swiss Exchange and short-term guidance for 2026.
ALC.SW stock: earnings setup and calendar
Alcon (ALC.SW) will publish results after the US market close on 24 Feb 2026. The upcoming report is the main catalyst for short-term trading and will cover Surgical and Vision Care segment trends. Analysts will watch guidance, margin commentary, and any update to capital allocation or buybacks. For reference, the last announced EPS was 1.61 and the trailing PE is 39.93.
ALC.SW stock: recent price action and valuation
The share price sits at CHF 63.78, near the 50-day average of CHF 62.90 and below the 200-day average of CHF 65.60. Year high is CHF 87.00 and year low CHF 57.68, a 1-year return of -20.21%. Valuation ratios point to premium multiples: P/S 4.03 and P/B 1.85, while EV/EBITDA is 21.80. Those metrics frame whether the earnings beat justifies measured upside.
ALC.SW stock: segment performance and financial metrics
Alcon’s Surgical and Vision Care segments drive revenue per share of 20.65 and operating cash flow per share of 4.15. Free cash flow per share equals 3.22 and shareholders’ equity per share is 44.74. Debt remains modest with debt to equity of 0.24 and interest coverage of 7.25. These figures support durable cash generation even if procedure volumes fluctuate.
ALC.SW stock: technicals and liquidity
Technical indicators show bullish momentum but higher short-term risk. RSI is 60.38, CCI at 207.54 signals short-term overbought conditions, and ATR is 1.47 CHF. Average daily volume is 1,088,621; today’s volume was 1,077,533, keeping liquidity robust on the SIX exchange. Traders should expect widened spreads around the earnings print.
Meyka AI rates ALC.SW with a score out of 100
Meyka AI rates ALC.SW with a score out of 100: 74.50 (Grade B+) with a suggestion to BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The proprietary score blends growth and valuation signals but is not a guarantee. Use the grade alongside your own research and risk limits.
ALC.SW stock: risks, catalysts and price targets
Near-term catalysts include the 24 Feb 2026 earnings, surgical volume recovery, and guidance updates. Risks include procedure timing shifts and persistent margin pressure in market access. Reasonable price targets: conservative CHF 55.00, base CHF 64.00, bull CHF 75.00. These targets reflect current PE of 39.93 and scenario-based revenue assumptions.
Final Thoughts
Key takeaways for ALC.SW stock: Alcon closed at CHF 63.78 on 23 Feb 2026 with EPS 1.61 and a stretched PE of 39.93, setting high expectations ahead of earnings on 24 Feb 2026. Meyka AI’s forecast model projects a one-year target of CHF 61.27, implying a -3.96% downside versus today’s price. Forecasts are model-based projections and not guarantees. Investors should weigh durable free cash flow per share of 3.22, modest leverage, and surgical volume trends against valuation. For traders, technical overbought signals invite caution; for longer-term investors, the B+ Meyka grade flags attractive fundamentals but limited near-term upside. We track the earnings release and will update analysis once management provides guidance. For company details see the official Alcon site and company page Alcon investor site and Alcon LinkedIn. Meyka AI provides this piece as an AI-powered market analysis platform
FAQs
When does Alcon report earnings and how could that move ALC.SW stock?
Alcon reports on 24 Feb 2026. Earnings, guidance, and surgical volumes can move ALC.SW stock sharply. Expect wider intraday spreads and volatility as traders price new revenue and margin signals.
What are the main valuation metrics to watch for ALC.SW stock?
Key metrics include PE 39.93, P/S 4.03, EV/EBITDA 21.80, and free cash flow per share 3.22. These show premium valuation versus some healthcare peers and set expectations for growth.
What does Meyka AI forecast for ALC.SW stock and what is the caveat?
Meyka AI’s forecast model projects CHF 61.27 for the year, an implied -3.96% from CHF 63.78 today. Forecasts are model-based projections and not guarantees.
What are the main risks that could hurt ALC.SW stock after earnings?
Risks include weaker surgical procedure volumes, margin compression, and slower Vision Care sales. Currency swings and reimbursement pressures could also weigh on ALC.SW stock performance.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.